Recurrence of macular edema associated with branch retinal vein occlusion after intravitreal bevacizumab (Q34106112)

31 July 2017

title

Recurrence of macular edema associated with branch retinal vein occlusion after intravitreal bevacizumab (English)

1 reference

31 July 2017

1 reference

retinal vein occlusion

1 reference

Narihisa Hanada

1

1 reference

31 July 2017

Hiroyuki Iijima

series ordinal

2

1 reference

31 July 2017

Yoichi Sakurada

series ordinal

3

1 reference

31 July 2017

Mitsuhiro Imasawa

series ordinal

4

1 reference

31 July 2017

publication date

20 December 2011

1 reference

Japanese Journal of Ophthalmology

31 July 2017

published in

1 reference

31 July 2017

volume

56

1 reference

31 July 2017

issue

2

1 reference

31 July 2017

page(s)

165-174

1 reference

Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6.

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10384-011-0113-4

The effects of intravitreal bevacizumab on patients with macular edema secondary to branch retinal vein occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-011-0113-4

Safety and efficacy of intravitreal bevacizumab (avastin) for the management of branch and hemiretinal vein occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-011-0113-4

One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-011-0113-4

Intravitreal injection of bevacizumab for macular edema secondary to branch retinal vein occlusion:results after 12 months and multiple regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-011-0113-4

Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-011-0113-4

Visual acuity following intravitreal bevacizumab for macular edema associated with retinal vein occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-011-0113-4

Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-011-0113-4

Early intravitreal bevacizumab for non-ischaemic branch retinal vein occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-011-0113-4

Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-011-0113-4

Intravitreal triamcinolone acetonide versus bevacizumab therapy for macular edema associated with branch retinal vein occlusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-011-0113-4

Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema secondary to branch retinal vein occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-011-0113-4

Comparison of bevacizumab and triamcinolone for treatment of macular edema secondary to branch retinal vein occlusion in a pair-matched analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-011-0113-4

Comparison between intravitreal bevacizumab and triamcinolone for macular edema secondary to branch retinal vein occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-011-0113-4

The treatment of branch retinal vein occlusion with bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-011-0113-4

Long-term follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-011-0113-4

Risks of intravitreous injection: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-011-0113-4

Sterile endophthalmitis after intravitreal injection of bevacizumab obtained from a single batch

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-011-0113-4

Topography of diabetic macular edema with optical coherence tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-011-0113-4

Sectoral thinning of the retina after branch retinal artery occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-011-0113-4

Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-011-0113-4

Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-011-0113-4

Effect of intravitreal bevacizumab (IVB) in treating macular edema secondary to branch retinal vein occlusion (BRVO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-011-0113-4

Intravitreal bevacizumab versus triamcinolone acetonide for macular edema due to branch retinal vein occlusion: a matched study

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22183139

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22183139

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22183139

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10384-011-0113-4

1 reference

Dimensions Publication ID

31 July 2017

1045673853

0 references

1 reference